Ritonavir (NRV) — Competitive Intelligence Brief

Ritonavir (NRV) (Ritonavir (NRV)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor. Area: Infectious disease.

phase 3 Protease inhibitor HIV protease Infectious disease Small molecule

Target snapshot

Ritonavir (NRV) (Ritonavir (NRV)) — French National Agency for Research on AIDS and Viral Hepatitis. Ritonavir is a protease inhibitor that blocks the protease enzyme, preventing viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ritonavir (NRV) TARGET	Ritonavir (NRV)	French National Agency for Research on AIDS and Viral Hepatitis	phase 3	Protease inhibitor	HIV protease
Lopinavir/ritonavir 4:1	Lopinavir/ritonavir 4:1	Drugs for Neglected Diseases	marketed	HIV protease inhibitor	HIV protease
Active comparator: DRV/cb	Active comparator: DRV/cb	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	marketed	HIV protease inhibitor with pharmacokinetic booster	HIV protease
Darunavir, Ritonavir and Rilpivirine	Darunavir, Ritonavir and Rilpivirine	St Stephens Aids Trust	marketed	Antiretroviral combination (protease inhibitor + NNRTI)	HIV protease, HIV reverse transcriptase
Kaletra + Current Dual NRTI Backbone	Kaletra + Current Dual NRTI Backbone	University of Chicago	marketed	Protease inhibitor combination	HIV protease
Darunavir, Ritonavir and Etravirine	Darunavir, Ritonavir and Etravirine	Imperial College London	marketed	Antiretroviral combination (protease inhibitor + NNRTI)	HIV protease, HIV reverse transcriptase
Darunavir/Cobicistat (FDC)	Darunavir/Cobicistat (FDC)	Janssen Scientific Affairs, LLC	marketed	HIV protease inhibitor with pharmacokinetic booster	HIV protease; CYP3A4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor class)

1. Pfizer · 4 drugs in this class
2. French National Agency for Research on AIDS and Viral Hepatitis · 4 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. Christopher J. McLeod · 1 drug in this class
5. Hoffmann-La Roche · 1 drug in this class
6. Janssen R&D Ireland · 1 drug in this class
7. Janssen-Cilag International NV · 1 drug in this class
8. Johns Hopkins University · 1 drug in this class
9. Medical Research Council · 1 drug in this class
10. Pfizer Inc. · 1 drug in this class